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Many infectious diseases are still prevalent in the world’s populations since no effective treatments are available to eradicate them.
e reasons may either be the antibiotic resistance towards the available therapeutic molecules or the slow rate of producing
adequate therapeutic regimens to tackle the rapid growth of new infectious diseases, as well as the toxicity of current treatment
regimens. Due to these reasons, there is a need to seek and develop novel therapeutic regimens to reduce the rapid scale of bacterial
infections. Antimicrobial Peptides (AMPs) are components of the first line of defense for prokaryotes and eukaryotes and have a
wide range of activities against Gram-negative and Gram-positive bacteria, fungi, cancer cells, and protozoa, as well as viruses. In
this study, peptides which were initially identified for their HIV inhibitory activity were further screened for antibacterial activity
through determination of their kinetics as well as their cytotoxicity. From the results obtained, theMICs of two AMPs (Molecule 3
and Molecule 7) were 12.5 μg/ml for K. pneumoniae (ATCC 700603) and 6.25 μg/ml for P. aeruginosa (ATCC 22108). e two
AMPs killed these bacteria rapidly in vitro, preventing bacterial growth within few hours of treatment. Furthermore, the cytotoxic
activity of these two peptides was significantly low, even at an AMP concentration of 100 μg/ml. ese results revealed that
Molecule 3 and 7 have great potential as antibacterial drugs or could serve as lead compounds in the design of therapeutic
regimens for the treatment of antibiotic-resistant bacteria.
1. Introduction
e human body is equipped with a defence mechanism,
which enables it to eradicate foreign bodies and/or patho-
genic organisms [1, 2]. However, the inability of the human
defence system to defend itself following a microbial in-
vasion of the immune system will ultimately result in
complete immunity breakdown, hence giving way for the
entrance of other pathogenic organisms into the body.
While most bacteria cohabitate with human cells without
causing any harm and disruption, some common infectious
pathogens that would cause diseases may include the
Methicillin-resistant Staphylococcus aureus (MRSA) strains,
Candida albicans, Herpes simplex, Mycobacterium avium
complex (MAC), Mycobacterium tuberculosis, Klebsiella
pneumoniae, and Pseudomonas aeruginosa, just to name a
few [3]. S. aureus, K. pneumoniae, E. coli, and P. aeruginosa
are examples of bacteria that have serious clinical and
medical implications in individuals, and these bacteria ac-
count for the major causes of nosocomial infections
worldwide [4, 5]. In addition, these pathogenic microbes
have been cited as the major causative agents for many
infections such as skin infections, respiratory infections, and
other major illnesses. In some instances, these infections can
lead to life-threatening diseases such as pneumonia, men-
ingitis, toxic shock syndrome, and bacteremia [5–7].
Hindawi
International Journal of Microbiology
Volume 2020, Article ID 2131535, 9 pages
https://doi.org/10.1155/2020/2131535
Besides the fact that the immune system of some indi-
viduals cannot withstand any bacterial infection, the main
problem is that the currently available antibiotics used to
eradicate these pathogenic microbes are ineffective. Such
ineptitude of new antibiotics is a result of the microbial
resistance towards them. Furthermore, immunocompetent
individuals infected with S. aureus, P. aeruginosa, and/or K.
pneumoniae have also demonstrated low susceptibility to
these drugs due to antibiotic resistance genes [8–11].
e lack of effective antibacterial antibiotics to inhibit
the infectious pathogens and to stop the ability of these
microorganisms to replicate has encouraged microbiologists
and clinical pathologists to embark on a journey in search of
alternative remedies to treat such microbial infections. Some
antimicrobial peptides have proven to be good sources of
antibacterial activity [12–17].
A number of these peptides have been commercially
developed and are available on the market. Some examples
include the US FDA-approved Polymixin B-Collistin-
Colomycin (prodrug) and Daptomycin (Cubicin) which are
used to treat skin infections [18, 19]. Likewise, the imple-
mentation of AMPs has yielded substantial results in
demonstrating their activity against Gram-positive and
Gram-negative bacteria, protozoa, fungi, viruses, and spe-
cifically HIV [20–26].
In a previous study, we were able to identify and validate
AMPs with potent anti-HIV activity [27]. Some of these
AMPs were also used as ligands for the diagnosis of HIV
[28, 29]. A follow-up study describing the in-silico site-
directed mutagenesis of the parental anti-HIV AMPs to
increase their binding affinity was carried out, and the anti-
HIV activity demonstrated that these mutated AMPs have
increased anti-HIV activity as compared to their parental
AMPs. Furthermore, the broad neutralizing ability and the
mechanism of action of these anti-HIV AMPs were dem-
onstrated as well (unpublished data, a manuscript is in
preparation). However, in the current study, we screened
these peptides against a number of Gram-positive and
Gram-negative bacteria to investigate if these antimicrobial
peptides could have antibacterial activity besides their anti-
HIV activity. e antibacterial experiment was also to
confirm the efficacy of the bioinformatics method used to
identify peptides with diverse microbial activities. e re-
sults showed that some of the AMPs have moderate activity
against Gram-positive bacteria. However, the peptides ex-
hibit potent activity against the Gram-negative bacteria such
as Klebsiella pneumoniae (ATCC 700603) and Pseudomonas
aeruginosa (ATCC 22108) that are clinical antibiotic-
resistant strains. Moreover, some peptides with antibacterial
activity proved to have a fast killing kinetic within a rea-
sonable time against these bacteria. eir cytotoxicity ac-
tivity toward human cell lines was also significantly low.
2. Materials and Methods
2.1. Bacterial Strains. e antibacterial activity of the pu-
tative antimicrobial peptides was carried out on Staphylo-
coccus aureus spp., a Gram-positive bacterium obtained
from the American Type Culture Collection (ATCC), with
the S. aureus spp. comprising of the methicillin-sensitive S.
aureus (ATCC 25923) and the methicillin-resistant S. aureus
(ATCC 33591) strains.e other bacterial strains tested were
K. pneumoniae (ATCC 700603) and P. aeruginosa (ATCC
22108) which are Gram-negative bacteria.
2.2. Antimicrobial Peptide Compounds. Five putative anti-
HIV AMPs were utilized for the antibacterial assay (Table 1),
and their physicochemical properties were characterized
(Table 2). e AMPs were identified as described in a
previous work by Tincho [27]. e selected AMPs were
obtained from GL Biochem Ltd. (Shanghai 200241, China),
and they were chemically synthesized using the solid-phase
method and they were purified to> 98 % by reverse-phase
High-Pressure Liquid Chromatography.
2.3. Preparation of Antimicrobial Peptides and Positive
Control Concentration. A stock solution of AMPs was
prepared by dissolving an amount of AMPs in sterile dis-
tilled water (dH2O), and the various AMP working con-
centrations used in the microtiter broth dilution assay were
prepared in two-fold serial dilutions starting at a concen-
tration of 500 μg/ml to 1.5625 μg/ml. Ampicillin was utilized
as the positive control in this assay and a working stock
solution of 100 μg/ml was prepared in distilled water.
2.4. Antimicrobial In Vitro Assays
2.4.1. Antibacterial Activities and Minimum Inhibitory
Concentration (MIC). emicrotiter broth dilution method
was employed to measure the antibacterial activity of the
AMP’s. e assay was performed according to the standards
and guidelines as stipulated in the Clinical and Laboratory
Standards Institute (CLSI) [30]. In brief, the test microor-
ganisms (MRSA (ATCC 33591), MSSA (ATCC 25923), K.
pneumoniae (ATCC 700603), and P. aeruginosa (ATCC
22108)) were grown to the midlogarithmic phase in Tryptic
Soy Broth (TSB) on a shaker set at 37°C and shaking at
150 rpm. e turbidity was adjusted to a 0.5 McFarland
standard with a final volume of 10ml. From the stock of
prepared AMP solutions, various working peptide con-
centrations (500 μg/ml to 1.5625 μg/ml) were prepared, and
amixture of the bacteria with the peptides was incubated in a
96 well flat bottom plate for 24 h at 37°C. Following 24 h
incubation, 40 μl of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
phenyl-2H-tetrazolium (INT) was added to each well and
incubated again for 3 h. Absorbance readings were taken at
620 nm on a microtiter plate reader (Omega®POLARstarBMG Labtech, USA).
All the antibacterial assays of the AMPs were prepared in
triplicate, and the experiments were repeated three times to
ensure the reproducibility of the testing. Absorbance results
were exported into an Excel file, where they were trans-
formed into a percentage, in a Normalizing process. e
MIC of each peptide was defined as the concentration
resulting in about 90% killing of the initial inoculums.
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2.4.2. Growth Inhibitory Assay. e growth curves for K.
pneumoniae (ATCC 700603) and P. aeruginosa (ATCC
22108) treated with Molecule 3 and Molecule 7 over time
were determined based on measurements taken at 620 nm at
each collection time. Different concentrations of the peptide
were added to the tested strains (K. pneumonia and P.
aeruginosa), which were cultured in 96 well plates using the
same method as used for the determination of the antimi-
crobial activity of the AMPs and the MIC.
2.5. Cytotoxicity. e cytotoxicity activity of the AMPs was
measured by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as described by
Freimoser [31]. In brief, after the trypsinisation of HEK293T
and HepG2 cells, 1× 104 cells/well were seeded in a 96-well
sterile plate and grown to confluence in Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum. Molecule 3
and Molecule 7 were each added to the wells at different
concentrations (10 μg/ml, 25 μg/ml, 50 μg/ml, and 100 μg/
ml). Cells treated with 6% DMSO served as positive control.
After 48 h after treatment with the peptides, 20 μl of MTT
solution was added to each well, and the plates were in-
cubated in a humidified incubator for 3 h in 5% CO2 at 37°C.
After incubation, the media was removed and dimethyl
sulfoxide (DMSO) (100 μl per well) was added into each well
and the plate was again incubated in a shaker at 37°C, 5%
CO2 incubator for 10min. e plates were gently swirled for
10min at room temperature to dissolve the precipitate. e
absorbance was determined using a multiplate reader
(Omega®POLARstar BMG Labtech, USA) at a wavelengthof 570 nm, 600 nm, and 630 nm.
e assay was repeated three times to confirm the re-
producibility of the experiment. e final absorbance of the
treated cells was obtained by subtracting the background
absorbance of the multi-well plate at 630 nm and from the
570 nm measurements. e percentage cell viability was
calculated using the following formulae:
Cell viability (%) �
OD570 − OD630( 􏼁(Treated sample)
OD570 − OD630( 􏼁(Untreated control)
× 100.
(1)
Absorbance results were exported into an Excel file,
where they were transformed into a percentage, in a process
called normalizing.
2.6. Statistical Analysis. e data presented are means± SD
obtained from at least three independent experiments. e
statistical analysis and the cytotoxicity values of each pu-
tative AMP were performed using GraphPad Prism software
(GraphPad software, San Diego, CA, USA). e differences
between the means were considered to be significant if
p< 0.05 according to Prism’s two-way ANOVA test. Stan-
dard error bars represent the s.d. of the mean (±s.d.) and
∗p< 0.05 denoted the significant differences between the
means of the untreated and treated cells.
3. Results
3.1. ;e In Vitro Antibacterial Activity of the Antimicrobial
Peptides. e antibacterial activities of the identified AMPs
were studied using the microtiter method as prescribed by
the CLSI standard. Initial screening of these peptides showed
that two AMPs (Molecule 3 and Molecule 7) have more
effective antibacterial activity on Gram-negative bacteria, as
compared to Gram-positive bacteria (Table 3). Further ex-
periments to determine the MICs of the tested AMPs with

























Molecule 1 8903.716 11.39 6.33 16 8.37 +6 34 2.17 kcal/mol
Molecule 3 4040.889 18.92 8.11 0.00 11.86 +8 43 1.37 kcal/mol
Molecule 7 4073.940 18.92 8.11 0.00 11.46 +7 43 1.45 kcal/mol
Molecule 8 3670.552 14.71 5.88 17.65 9.60 +8 38 1.07 kcal/mol
Molecule
10 3908.564 11.11 5.56 0.00 10.33 +2 47 1.33 kcal/mol
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antibacterial activity showed that the MICs of Molecule 3
were 12.5 μg/ml for K. pneumoniae (ATCC 700603) and
6.25 μg/ml for P. aeruginosa (ATCC 22108). e same MICs
values were observed for Molecule 7 with K. pneumoniae
(ATCC 700603) and P. aeruginosa (ATCC 22108).
e data suggest that the Gram-negative bacteria were
more sensitive to Molecule 3 and Molecule 7, with more
effective inhibitory activities toward the antibiotic-resistant
pathogens than the traditional antibiotic drugs. However,
Gram-positive bacteria (MRSA (ATCC 33591) and MSSA
(ATCC 25923)) were both insensitive to these peptides
(Molecule 3 and 7).
3.2. Growth Inhibitory Activities of Molecule 3 andMolecule 7
on the Bacteria. In addition to the determined MICs, we
investigated the rate at which the peptides influence the
bacterial growth over time (Figures 1 and 2). e OD620 was
measured from 3 to 8 h after treatment with a microplate
reader, with Ampicillin as a positive control. It was found
that both peptides (Molecule 3 and molecule 7) could inhibit
K. pneumoniae (ATCC 700603) and P. aeruginosa (ATCC
22108) growth at concentrations of 25 μg/ml and lower, at a
very short period of time after treatment (Figures 1 and 2). It
was noticed that even with an AMP concentration lower
than the determined MIC, Molecule 3 and 7 could still
completely inhibit P. aeruginosa (ATCC 22108) growth
3–8 h after treatment (Figures 1(a) and 2(a)). However,
Molecule 3 was able to inhibit P. aeruginosa at all the
concentrations and for the duration of the experiment, while
Molecule 7 could not inhibit P. aeruginosa growth at con-
centrations lower than the MIC (6.25 μg/ml) (Figure 2(a)).
Similarly, Molecule 7 could not suppress the growth of K.
pneumoniae (ATCC 700603) at concentrations lower than
the respective MIC values obtained for Molecule 7 on these
organisms (Figure 2(b)). Molecule 3 was able to suppress the
growth of K. pneumoniae (ATCC 700603) at concentrations
equal to the MIC (12.5 μg/ml) and 2x MIC higher than the
MIC. At concentration of 6.25 μg/ml, Molecule 3 was able to
suppress growth for a period of 4 h (Figure 1(b)). Fur-
thermore, the positive control, ampicillin, could inhibit the
growth of P. aeruginosa (ATCC 22108) at a concentration of
100 μg/ml. However, the same concentration of ampicillin
(100 μg/ml) failed to inhibit the growth of K. pneumoniae
(ATCC 700603). e possibility to inhibit the growth of K.
pneumoniae (ATCC 700603) and P. aeruginosa (ATCC
22108) at different AMPs concentrations demonstrated that
the inhibitory effect of these AMPs is dose-dependent.
3.3. Cytotoxicity Activity of Molecule 3 and Molecule 7 on
HEK293T and HepG2 Cell Lines. e cytotoxicity of Mole-
cule 3 and Molecule 7 against mammalian cells HEK293T
andHepG2 were tested by anMTTmethod (Figures 3(a) and
3(b)), using a dose-response assay (concentrations of 25, 50,
75, and 100 μg/ml were used). Molecule 3 and Molecule 7
induced a dose-dependent decrease in the viability of the
two-cell lines tested in this study. Only a moderate decrease
in cell viability was observed for both peptides (Molecules 3
andmolecule 7), even at the highest peptide concentration of
100 μg/ml, with a cell viability of 79.5% for the HepG2 cell
line. However, considerable (p< 0.0001) cytotoxicity as
compared to the untreated cell line (negative control) was
observed whenHEK 293Tcell line was treated withMolecule
3 and Molecule 7 with a cell viability of only 59.29%.
Nevertheless, when the peptide concentration used is 25 μg/
ml, both cell lines inhibition are more than 90% (Figures 3(a)
and 3(b)). But, at this concentration, Molecule 3 and 7 ef-
fectively inhibited the growth of the Gram-negative bacteria,
including K. pneumonia (ATCC 700603) and P. aeruginosa
(ATCC 22108), showing that these peptides would be less
toxic to normal human cells.
4. Discussion
e medical and pharmaceutical industries are in a race to
discover and develop novel drugs that would serve as potent
antimicrobials to combat several diseases. is journey is a
time-consuming process, demands a lot of funds, and
sometimes ends up being rejected at the clinical trial stages
due to numerous side effects. Another major problem with
new antibiotics developed in the past decade is the increase
in bacterial resistance to available antibiotics, which is
caused by abuse of antibiotic. Potent antimicrobial peptide-
based drugs can possibly counter the antibiotic-resistance.
In the quest to search for novel peptide-based antibiotics,
we screened a number of AMPs for antibacterial activity
using the microtiter method. From the results, it was shown
that only two antimicrobial peptides were able to completely
inhibit the growth of P. aeruginosa and K. pneumonia at the
respective AMP concentration of 6.5 μg/ml and 12.5 μg/ml
(Table 3). Even the highest AMP concentration of 500.0 μg/
ml was not able to inhibit up to 50% of both treated
Staphylococcus spp. even for the methicillin-sensitive
Staphylococcus aureus (MSSA). is was also true for the
methicillin-resistant Staphylococcus aureus (MRSA). Only
moderate bacterial inhibitions were observed 24 h after
treatment of both Staphylococcus spp. with 500.0 μg/ml
AMP concentrations (Data not shown).
From the results, we observed that Molecule 3 and 7 have
similar Lys and Arg percentage composition and these two
amino acids are the most common residues in these two
peptides among the tested antimicrobial peptides (Table 1
and Table 2); and these amino acids have been documented
to be important for the cationic function of AMPs [32–34].
Furthermore, the two AMPs have similar isoelectric po-
tential and both AMPs have the best positively charged
parameters as compared to the other tested peptides (Ta-
ble 2). Additionally, the presence of the positively charged




MRSA MSSA K. pneumoniae P. aeruginosa
Molecule 1 >500 >500 500 >500
Molecule 3 >500 >500 12.5 6.25
Molecule 7 >500 >500 12.5 6.25
Molecule 8 >500 >500 >500 >500
Molecule 10 >500 >500 500 >500
Ampicillin >100 >100 >100 100
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residues and a hydrophobicity of 43% are excellent elements
that enable these peptides to have better antibacterial activity
as opposed to the three other peptides [35–37].
e differences observed in antibacterial activity against
Gram-negative and Gram-positive bacteria could be
explained by the differences in cell wall chemistry. Gram-
negative bacteria have an additional outer membrane, which
makes them more resistant to conventional antibiotics [38,
39]. us, the greater activity of the AMPs against Gram-
negative bacteria is a promising result. e use of novel
molecules such as AMPs on antibiotic-resistant bacteria
could, therefore, serve as an additional template for drugs
design against these antibiotic-resistant bacteria. e results
obtained in this study could also be explained by the
presence of a single layer of heavy peptidoglycan volume in































































Figure 1: Growth-inhibitory effects of Molecule 3 against P. aeruginosa (ATCC 22108) and K. pneumoniae (ATCC 700603). (a) e time
curve of Molecule 3 against P. aeruginosa (ATCC 22108). (b) e time curve of Molecule 3 against K. pneumoniae (ATCC 700603). e


























































Figure 2: Growth-inhibitory effects of Molecule 7 against P. aeruginosa (ATCC 22108) and K. pneumoniae (ATCC 700603). (a) e time
curve of Molecule 7 against P. aeruginosa (ATCC 22108). (b) e time curve of Molecule 7 against K. pneumoniae (ATCC 700603). e
tested strain was cultured in 96-well plates, and the OD620 was measured at each time point.e error bars indicate standard deviations from
the mean.
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prevent the destruction of the Staphylococcus spp. by the
AMPs. In contrast, the Gram-negative bacteria have a light
peptidoglycan layer with an extra outer membrane; thus, the
tested bacteria (P. aeruginosa (ATCC 22108) and K. pneu-
moniae (ATCC 700603)) were sensitive to the AMPs. Hence,
it can be said that the role of sugar moieties (N-linked sugars,
peptidoglycans, and lipopolysaccharides) on the microor-
ganism’s membrane is to protect them against neutralizing
antibodies and antibiotics in certain situations [40–42].
Although the result points out that 100 μg/ml ampicillin
could not inhibit the growth of K. pneumonia, moreover, it
was observed that this bacterium seemed to grow more than
the untreated bacterium when treated with 100 μg/ml am-
picillin. Lin et al. reported the same observation in 2013,
when K. pneumonia was treated with 5mg/ml of Fructus
mume seems to growmore than the untreated K. pneumonia
after the second hour after experiment; later, the treated
bacterium stop growing than the untreated one and surpass
the untreated bacterium from the 24 h after treatment [43].
e patterns of the untreated K. pneumonia and the treated
K. pneumonia with 5mg/ml of Fructus mume reported in
this study are similar to the curve recorded for the untreated
K. pneumonia and the K. pneumonia treated with 100 μg/ml
Ampicillin (Figures 1(b) and 2(b)).
e ability of these two antimicrobial peptides to inhibit
the Gram-negative bacteria P. aeruginosa (ATCC 22108) and
K. pneumoniae (ATCC 700603) also demonstrates that the
model developed for the antimicrobial peptides is to be
taking into consideration as future tool for the design and
the identification of potent peptides with broad microbial
activities. Although the initial bioinformatics models were
developed to identify AMPs with HIV activity, it does limit
these AMPs just to the HIV activity since it has previously
been showed that a single antimicrobial peptide may exert
multiple antimicrobial activities [44–50].
Many AMPs have been proven to have antibacterial
activity on selected pathogenic microbes [12–17, 49], and
even though most of these AMPs have not passed the final
stage of clinical trials and only few are used [50–52], the
current antibacterial activity exhibited by the two AMPs
look promising since the peptides are more active than a
known antibiotic, ampicillin on K. pneumoniae (ATCC
700603) (Figures 1(b) and 2(b)). Furthermore, Molecule 3
and Molecule 7 kill P. aeruginosa (ATCC 22108) and K.
pneumoniae (ATCC 700603) at a fast rate and still maintain
their activity for a long period after treatment. is ability,
thus, qualifies Molecule 3 and molecule 7 as being bacte-
ricidal. In addition, both AMPs (Molecule 3 andMolecule 7)
have a reduced toxicity to the HEK293Tcell line with a lesser
cytotoxicity of the AMPs observed onHepG2 cell line (a type
of human liver cancer cell line). e selective toxicity of the
AMPs is probably due to differences in the membranes
between the mammalian cells and the bacteria.
Despite the fact that the mechanism of action by which
Molecule 3 and Molecule 7 exert their antibacterial activity
has not yet been established, the bactericidal ability of these
AMPs could be a result of either using the Barrel–stave
mechanism, the carpet mechanism [53], or the toroidal pore
mechanism [24]. e barrel–stave mechanism is more likely
since most of our peptides are α-helical, β-sheet peptides,
extended with α-helical structure, and extended with β-sheet
structure; and it has been found that most α-helical or
β-sheet AMPs use this mechanism to exert their activity on
pathogens [54]. e antibacterial activity displayed by both
Molecule 3 and Molecule 7 against P. aeruginosa (ATCC













































































Figure 3: Cytotoxicity of Molecule 3 and Molecule 7 to mammalian cells. (a) Cytotoxicity of Molecule 3 to HepG2 and HEK293Tcell lines.
(b) Cytotoxicity of Molecule 7 to HepG2 and HEK293T cell lines. Cytotoxicity was measured with an MTT assay. e concentrations of
Molecule 3 and Molecule 7 ranged from 0 to 100 μg/ml. e positive control was 6.0% DMSO. e error bars indicate standard deviations
from the mean. ∗∗∗∗ Statistical significance (p< 0.001) compared to negative control.
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toxicity on HEK293Tand HepG2 cell lines suggest that these
two AMPs may be good lead compounds for the design of
effective antibacterial drugs of peptide origin.
5. Conclusion
e exploration of additional and new medications to
combat many infectious diseases is the ultimate goal of
most research facilities and/or pharmaceutical companies
around the world. It has become imperative that we find
novel lead molecules that can be utilized for the devel-
opment of these new drugs to which the pathogens are
sensitive. Here, a set of peptides, previously shown to have
HIV activity, have demonstrated rapid bactericidal activity
against pathogenic Gram-negative bacteria. Additionally,
both AMPs with antibacterial activity are less toxic on
HEK293T and HepG2 cell lines, even at concentration 4X
higher to the bacterial MIC. ese results demonstrate that
these peptides are clinically important and are an excellent
template to design an anti-infective drug. Further works
will be to test the peptide activities on clinical strains,
establish the mechanism of action of the antimicrobial
peptides, and perform in vivo testing of the peptides to
confirm their antibiotic potential.
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